Eye cancer · Treatments

Eye Cancer Treatment Options: How Eye Tumors Are Treated Today

Eye cancer is treated with radiation aimed at the tumor, laser and light, chemotherapy given directly to the eye, surgery or, if it has spread, medicines for the whole body. Most eyes with cancer can now be kept: for a medium-sized uveal melanoma, a radioactive plaque protects life as well as removing the eye does. The right choice depends on the tumor's type, size and position, the vision in both eyes, age, general health and your own priorities.
Order of priorities
life first, then the eye, then vision
Radioactive plaque vs. removing the eye
same survival for medium-sized melanoma (COMS)
Tumor control in a 2026 series
about 95–96% after plaque or proton therapy
Cancer on the eye surface (OSSN)
chemotherapy eye drops are an alternative to surgery
Investigational as of September 2026
bel-sar, darovasertib before eye treatment, ATOM and OptimUM trials

The first time you hear the list of eye cancer treatments, it can feel like too much: radioactive plaques, proton beams, lasers, injections, eye drops, operations and new drugs. Yet most of them share one aim: to control the tumor and, whenever it is safe, keep the eye and as much sight as possible.

This page explains in plain words what each method does, which tumors it suits and what it means for your eye. The table links to a separate page for each tumor type.

What are the goals of eye cancer treatment?

Every plan weighs three goals, in this order: control the cancer and protect life, keep the eye, and save as much vision as possible.

The shift toward keeping the eye rests on solid evidence. A large American trial, the COMS, studied people with a medium-sized choroidal melanoma, a melanoma in the layer of blood vessels under the retina. They lived just as long after a radioactive plaque as after removal of the eye.

85%

Of those treated with a plaque, 85% still had the eye 5 years later.

In a 2026 study from Dublin, 310 patients were followed for more than 6 years on average. The tumor was controlled in about 95–96% after a plaque or proton therapy, and about 94–96% of patients kept the eye.

Which treatment suits which eye tumor?

The table gives the usual first options for each tumor. It is a simplified guide: your own findings can change the choice.

Tumor Usual first options Is the eye kept?
Suspicious choroidal nevus or unclear spot Regular photographs and scans; treatment if it grows Yes
Small or medium uveal melanoma Radioactive plaque; proton or stereotactic radiotherapy; photodynamic therapy (PDT) or thermotherapy for selected small tumors Yes, in most cases
Large uveal melanoma, spread into the optic nerve or a blind, painful eye Removal of the eye (enucleation) with an orbital implant; radiotherapy for selected large tumors Sometimes
Iris melanoma Watching if stable; removal or radiotherapy if growing Usually
Retinoblastoma, small tumors Laser, thermotherapy or cryotherapy (freezing), often with chemotherapy Yes
Retinoblastoma, advanced Chemotherapy into the eye's artery or into a vein; injections into the eye for tumor "seeds"; removal of the eye in many very advanced cases Often, not always
Vitreoretinal lymphoma Methotrexate or rituximab injections into the eye; radiotherapy or treatment for the whole body Yes
Choroidal metastasis Treatment of the original cancer; radiotherapy or PDT for the eye Yes
Choroidal hemangioma (benign) Watching; PDT if fluid affects vision Yes
Ocular surface squamous neoplasia (OSSN) Chemotherapy or interferon eye drops, or removal with cryotherapy Yes
Conjunctival melanoma "No-touch" removal with cryotherapy; drops or radiotherapy afterward Usually
Conjunctival or orbital lymphoma (slow-growing) Low-dose radiotherapy; rituximab; doxycycline in selected cases Yes
Eyelid basal cell carcinoma Removal with the edges checked (Mohs surgery or frozen sections), then repair of the lid Yes
Other eyelid cancers (sebaceous, squamous, Merkel cell) Wider removal with the edges checked; radiotherapy or lymph node checks as needed Usually
Benign orbital tumors Watching, or complete removal through an operation on the eye socket (orbitotomy) Yes
Orbital rhabdomyosarcoma (children) Biopsy, then chemotherapy and radiotherapy Usually
Metastatic uveal melanoma Tebentafusp if HLA-A*02:01-positive; treatment aimed at the liver; immunotherapy; clinical trials Not applicable

When is watching enough?

Not every eye tumor needs treatment right away. Watching is an active choice when a growth is benign or when it is not yet clear whether a small dark spot is a harmless nevus or an early melanoma. It also makes sense when treatment would carry more risk than the tumor, as in some frail older people.

At each visit the spot is measured the same way, with photographs, ultrasound, OCT (a detailed scan of the retina) and autofluorescence images. Once it proves stable, the visits become less frequent. Documented growth is the main signal to treat.

How does radiation treat eye tumors?

Radiation is the most widely used eye-sparing treatment for uveal melanoma. It also treats retinoblastoma, lymphoma, metastases and some cancers of the eye surface, eyelids and orbit.

  • Plaque brachytherapy. A small disc with radioactive seeds, usually iodine-125 or ruthenium-106, is stitched to the eye over the tumor and removed a few days later. The dose falls off steeply with distance, which spares the rest of the eye. The plaque is planned and placed with radiation oncologists and medical physicists.
  • Proton beam therapy. A beam from outside the eye stops inside the tumor, guided by small markers stitched to the eye. It is used mainly for large tumors or tumors next to the optic nerve. Relatively few centers in the world offer it.
  • Stereotactic radiotherapy (Gamma Knife, CyberKnife or a linear accelerator) aims many beams at the tumor in one or a few sessions, without an operation on the eye.
  • External beam radiotherapy treats lymphoma, metastases in both eyes and some orbital tumors. In children with inherited retinoblastoma it is avoided whenever possible, because it raises the risk of a second cancer.

The tumor shrinks slowly, over months. Side effects mostly stay in the treated eye: cataract, dry eye and radiation damage to the retina or optic nerve. This damage can lower vision months or years later. Several of these effects can be treated, for example with injections into the eye or cataract surgery after tumor treatment. The page on proton therapy and stereotactic radiotherapy compares the methods that aim radiation from outside the eye.

Plaque brachytherapy: a small curved plaque carrying radioactive seeds is stitched to the outside of the eye over the tumor, delivers its dose from outside in, and is removed after a few days. Plaque withradioactive seeds Tumor Sclera (eye wall) Radiation dose (highest at thebase, prescribed to the tumorapex) ← Front of the eye
Figure Plaque brachytherapy: a small curved plaque carrying radioactive seeds is stitched to the outside of the eye over the tumor, delivers its dose from outside in, and is removed after a few days.

What do laser and light treatments do?

  • Photodynamic therapy (PDT). A light-sensitive drug, verteporfin, is given into a vein. A low-energy laser aimed at the tumor activates the drug, which closes the tumor's blood vessels. PDT is the usual first choice for a circumscribed (well-defined) choroidal hemangioma, a benign blood-vessel tumor, when it causes symptoms. It also treats selected small melanomas and metastases. Small melanomas can come back after PDT alone, so close checks are essential.
  • Transpupillary thermotherapy (TTT) heats the tumor with an infrared laser through the pupil. After TTT alone, tumors often come back, so today it is mainly combined with a plaque.
  • Laser photocoagulation treats small retinoblastomas at the back of the eye and tumors of the retina's blood vessels, such as the hemangioblastomas of von Hippel-Lindau disease.

Prof. Dr. Elif Betül Türkoğlu, an ocular oncologist in Antalya, has researched PDT for melanoma herself.

What is cryotherapy?

Cryotherapy destroys tumor cells by freezing them with a fine probe. It treats small retinoblastomas near the front edge of the retina and some tumors of the retina's blood vessels. After a tumor is removed from the conjunctiva (the thin, clear membrane over the white of the eye), the wound edges are frozen and thawed two or three times. This lowers the chance that stray tumor cells stay behind. Temporary swelling and discomfort are common afterward.

How can chemotherapy be given straight to the eye?

Giving chemotherapy directly to the eye concentrates the drug where it is needed.

  • Eye drops. Courses of 5-fluorouracil, interferon alfa-2b or mitomycin C drops treat OSSN, precancerous or cancerous growths on the eye surface. Mitomycin C or interferon also treats precancerous pigment on the conjunctiva. For OSSN, a 2022 review of pooled studies found no significant difference between drops and surgery in how often the growth cleared or came back, but the evidence is weak. Redness and stinging are common; effects on the rest of the body are not expected.
  • Injections into the eye (intravitreal). Injections of melphalan or topotecan treat retinoblastoma "seeds" in the vitreous, the clear gel inside the eye. Methotrexate or rituximab injections treat vitreoretinal lymphoma. Prof. Türkoğlu led a research project on intravitreal melphalan for retinoblastoma that resisted treatment or came back. She was also first author of a 2017 congress presentation on rituximab with methotrexate injected into the eye for this lymphoma.
  • Injections into the front chamber of the eye are a new option, so far studied in only a few patients.
  • Intra-arterial chemotherapy. For retinoblastoma, a fine tube (catheter) is passed from the groin to the eye's own artery, and a drug such as melphalan is given straight into it. Interventional neuroradiologists do this, following a plan agreed with the ocular and pediatric oncologists. In a Wills Eye series of 341 eyes, 74% were saved at 5 years, more often when the tumor was less advanced. See intra-arterial and intravitreal chemotherapy.
  • Chemotherapy through a vein (vincristine, etoposide, carboplatin) is still important when retinoblastoma affects both eyes, in very young babies and after removal of an eye with high-risk features.

When is surgery needed?

Surgery remains central for tumors on the eye surface, in the eyelids and in the orbit.

  • Tumors on the eye surface are removed with a margin of healthy tissue, without touching the tumor ("no-touch" technique). The edges are frozen, and if the cornea is involved, its surface is treated with alcohol. Large gaps are covered with amniotic membrane or a graft.
  • Local resection cuts out selected tumors of the iris and ciliary body, and rarely of the choroid, while keeping the eye. It is demanding surgery for carefully chosen cases.
  • Eyelid cancers are removed with every edge checked under a microscope (Mohs surgery or frozen sections), and the lid is rebuilt. See eyelid cancer and eyelid surgery.
  • Orbital tumors are sampled or removed through the eyelid crease, the conjunctiva or the side of the orbit, or with an endoscope. See orbital tumors.
  • Enucleation, removal of the eye, is still the safest choice for very large tumors, for tumors that have spread into the optic nerve and for blind, painful eyes. An implant is placed during the operation, and a custom-painted artificial eye is fitted a few weeks later. An eye that may hold a tumor is removed whole. Evisceration, which removes only the contents of the eye, is reserved for eyes without cancer. See enucleation and eye prosthesis.
  • Orbital exenteration, removal of the contents of the eye socket, is needed only rarely, for cancers that have spread widely in the orbit.

Eye tumor surgery: what to expect explains anesthesia and recovery.

Which treatments work throughout the body?

When cancer has spread beyond the eye or cannot be controlled there, medical or pediatric oncologists give treatment for the whole body. The eye is still checked regularly.

  • Tebentafusp (Kimmtrak) is an approved immunotherapy. It turns the body's T cells, a kind of white blood cell, against uveal melanoma. It is for adults with metastatic or inoperable disease whose blood test shows the tissue type HLA-A*02:01. In its phase 3 trial, 16% were alive at 5 years with tebentafusp, compared with 8% with a treatment chosen by the trial doctors.
  • Treatment aimed at the liver, such as melphalan perfusion, surgery or ablation, is used for liver metastases in selected patients.
  • Checkpoint inhibitors, immunotherapy drugs that release the immune system's brakes, work less well in uveal melanoma than in skin melanoma. They have a role in advanced conjunctival melanoma and in squamous cell or Merkel cell carcinoma of the eyelid.
  • Targeted drugs. BRAF and MEK inhibitors treat conjunctival melanoma with a change in the BRAF gene. Hedgehog pathway inhibitors (vismodegib, sonidegib) treat advanced basal cell carcinoma and can sometimes spare the eye and socket from radical surgery.
  • Chemotherapy treats retinoblastoma, orbital rhabdomyosarcoma and widespread or aggressive lymphoma.

For uveal melanoma, see metastasis and follow-up.

Which new treatments are still being tested?

The treatments below are investigational. As of September 2026, they are available only in clinical trials, and their final results are not yet known. Phase 3 is usually the last and largest stage of testing before a treatment can be approved.

Trial What is tested Status as of September 2026
CoMpass (phase 3) Bel-sar (belzupacap sarotalocan), a drug switched on by light, versus a sham (dummy) treatment, for unclear spots and small choroidal melanomas 108 patients enrolled by June 2026; results expected in the second half of 2027
OptimUM-09 (phase 2), OptimUM-10 (phase 3) Darovasertib tablets before eye treatment, meant to shrink the tumor so that the eye can be kept or less radiation reaches the center of vision Phase 2: 57% of patients (24 of 42) who had been advised to have the eye removed and completed treatment kept the eye; phase 3 is enrolling
ATOM (phase 3, EORTC) Tebentafusp for up to 6 months after eye treatment versus observation, in HLA-A*02:01-positive patients at high risk First patient randomized in December 2024
OptimUM-11 (phase 3) Darovasertib plus crizotinib for 12 months after eye treatment versus observation First patient enrolled in September 2026
OptimUM-02 (phase 2/3) Darovasertib plus crizotinib for metastatic uveal melanoma in HLA-A*02:01-negative patients Submission to the US FDA in progress; not approved

Trials have strict entry rules and run only at the centers taking part. Ask your specialist whether you might qualify.

How is the treatment plan chosen?

A good plan is made with you, not for you. These are the main factors.

  • Tumor type and how sure the diagnosis is. A lymphoma, a metastasis and a melanoma of the same size are treated in completely different ways.
  • Size and position. Thickness and width count, and so does the distance from the fovea (the center of sharp vision) and the optic nerve. Doctors also check the ciliary body and any growth outside the eye.
  • Vision in both eyes. If the tumor is in your only seeing eye, protecting its sight matters even more.
  • Age and general health. Children need treatments that protect growth and avoid external radiation where possible. For some frail older people, a gentler approach may be wiser.
  • Genetics. Inherited retinoblastoma, caused by a change in the RB1 gene present from birth, affects treatment and the screening of relatives. In uveal melanoma, tumor genetics guide follow-up and entry to trials, and the HLA tissue type decides who can have tebentafusp.
  • Your priorities. How you weigh vision, the number of treatments, travel and time away from home.

For uveal melanoma, doctors group tumors as small, medium or large, as the diagram shows.

Size categories of choroidal melanoma used since the Collaborative Ocular Melanoma Study (COMS). Size is one of the strongest predictors of prognosis and guides the choice of treatment. Small 1–2.5 mm · 5–16 mm Medium 2.5–10 mm · ≤16 mm Large >10 mm or >16 mm height · base diameter
Figure Size categories of choroidal melanoma used since the Collaborative Ocular Melanoma Study (COMS). Size is one of the strongest predictors of prognosis and guides the choice of treatment.
  1. Records and examination. Both eyes are examined, and earlier images are compared.
  2. Measuring. The tumor is measured with imaging.
  3. Staging. A biopsy or body scans are done when the result would change the plan.
  4. Team review. Radiation, medical or pediatric oncologists join when their treatment is involved.
  5. Options explained. Benefits, risks and effects on vision, in plain words.
  6. Your decision. You have time for questions or a second opinion.
  7. Follow-up. Regular examinations and scans, shared with your doctors at home where possible.

Questions worth asking are listed in how to choose an ocular oncologist. What the cost depends on is explained in eye cancer treatment cost in Turkey.

What happens after treatment?

Follow-up is part of treatment. The eye is examined and scanned regularly, more often in the first years. These checks confirm that the tumor is under control and catch side effects early, while they can still be treated. After uveal melanoma, liver scans are planned according to your own risk. Children treated for retinoblastoma need checks for many years. All tumor types are introduced on the eye cancer overview.

Eye cancer treatment in Antalya

Prof. Türkoğlu sees adults and children at her practice in Antalya. She evaluates your case, explains the options and plans treatment with you. She performs eye tumor surgery herself: tumor removal and biopsy, removal of the eye with an implant (enucleation or evisceration), and eyelid and orbital surgery. Where a method needs special facilities, it is given together with the relevant specialist teams: radiation oncology and medical physics, interventional neuroradiology, and medical or pediatric oncology.

If you live in another city or country, you can start by sending your scans and reports for a remote second opinion. The international patients page explains travel and practical arrangements.

Guides to each treatment

Each treatment has its own page with the steps, results, risks and recovery.

Frequently asked questions

Can eye cancer be treated without removing the eye?

In most cases, yes. Radiation, light treatment, chemotherapy given directly to the eye and careful surgery allow most eyes with cancer to be kept. In a 2026 series of 310 people with uveal melanoma, about 94–96% kept the eye after a plaque or proton therapy. Removal is still advised when a tumor is very large, has grown into the optic nerve or has left the eye blind and painful.

Does radiation to the eye affect the rest of the body?

Usually not. Plaque, proton and stereotactic treatments aim the dose at the tumor itself, so side effects mostly stay in the treated eye. They include cataract, dry eye and radiation damage to the retina or optic nerve, which can lower vision months to years later. Some of these effects can be treated with injections, laser or cataract surgery.

Will I keep my vision after treatment?

It depends mainly on the size of the tumor and how close it lies to the center of the retina and the optic nerve. Small tumors away from these areas often leave good vision. Treatment close to them tends to lower sight over time. Regular checks and early treatment of radiation effects help protect the vision that remains.

Are chemotherapy eye drops or eye injections like ordinary chemotherapy?

No. Drops and injections into the eye act locally, so hair loss and feeling unwell are not expected. Drops often cause redness and irritation, though. Intra-arterial chemotherapy is designed to limit effects on the rest of the body. Still, the eyelids can swell for a while, and some children have low blood counts, which are monitored.

Is enucleation (removal of the eye) still needed today?

Sometimes. It remains the safest option for very large tumors, tumors that have grown into the optic nerve, some advanced retinoblastomas and eyes that have become blind and painful. An implant is placed during the same operation. A custom artificial eye is fitted a few weeks later and, in most everyday situations, looks natural.

Are new drugs such as bel-sar or darovasertib available?

Only in clinical trials. As of September 2026, bel-sar and darovasertib are investigational. In May 2026, a step-by-step (rolling) application to the US FDA began for darovasertib plus crizotinib in metastatic uveal melanoma; the combination is still not approved. Tebentafusp is approved for people with metastatic uveal melanoma who have the tissue type HLA-A*02:01.

How long does treatment take?

It depends on the method. Some treatments take a single session or operation. Radiotherapy, repeated injections or chemotherapy cycles take weeks to months, and years of check-ups follow. After your records are reviewed, you receive a proposed schedule. Travel planning is covered on the international patients page.

References

  1. National Cancer Institute. [Intraocular (uveal) melanoma treatment (PDQ), health professional version]. cancer.gov. cancer.gov
  2. [Plaque brachytherapy versus proton beam therapy for uveal melanoma: 310 patients treated in Dublin]. PubMed Central, 2026. pmc.ncbi.nlm.nih.gov
  3. [Meta-analysis of topical chemotherapy versus surgery for ocular surface squamous neoplasia]. Scientific Reports, 2022. nature.com
  4. Shields CL, et al. [Intra-arterial chemotherapy for retinoblastoma in 341 eyes: globe salvage at 5 years]. Journal of AAPOS, 2021. sciencedirect.com
  5. Piperno-Neumann S, et al. [Five-year overall survival with tebentafusp in metastatic uveal melanoma, phase 3 trial]. Annals of Oncology, 2026. sciencedirect.com
  6. Aura Biosciences. Aura Biosciences announces enrollment completion in Phase 3 CoMpass trial of bel-sar in early choroidal melanoma. Press release, 1 June 2026. globenewswire.com
  7. Ophthalmology Times. [Phase 2 OptimUM-09 results of neoadjuvant darovasertib in uveal melanoma, ESMO 2025]. 2025. ophthalmologytimes.com
  8. AllSci. [Darovasertib phase 3 trials in uveal melanoma, including OptimUM-10 and OptimUM-11]. 2026. allsci.com
  9. AllSci. [IDEAYA Biosciences initiates FDA submission for darovasertib plus crizotinib in metastatic uveal melanoma]. 2026. allsci.com
  10. EORTC. [First patient randomized in the ATOM trial of adjuvant tebentafusp]. December 2024. eortc.org
  11. Turkoglu EB, Pointdujour-Lim R, Mashayekhi A, Shields CL. Photodynamic therapy as primary treatment for small choroidal melanoma. Retina, 2019;39(7):1319-1325. PubMed
  12. Turkoglu EB, Rao R, Celik E. Long term outcome of adjuvant photodynamic therapy after CyberKnife radiotherapy for choroidal melanoma. Photodiagnosis and Photodynamic Therapy, 2022;38:102840. PubMed

Need an ocular oncology opinion?

Send your scans and reports for a review by Prof. Türkoğlu, or book a consultation in Antalya. Adults and children are seen.

Send a request